For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Chugai Sees Huge Potential in Its RAS Inhibitor with 15% of All Cancers Targeted: Research Chief
February 9, 2022
- Astellas’ Pompe Gene Therapy Proves Safe in PI/II Interim Data
February 9, 2022
- Japan Ethical Drug Sales Up 3.9% in December: Crecon
February 9, 2022
- Sales Reps’ Detailing Activities Decrease MOM, YOY in December: Intage
February 9, 2022
- New Disease Target Picked in Sosei-Takeda Drug Discovery Pact
February 9, 2022
- Sumitomo Dainippon to Boost Infectious Disease R&D, Eyes AMR/Malaria
February 8, 2022
- Insmed Plots Growth in Japan Biz with Arikayce and More Drugs to Follow
February 8, 2022
- Kyowa Kirin Nets 50%-Plus Sales from Overseas in 2021, Crysvita as Major Driver
February 8, 2022
- Cosentyx 75 mg Syringe Now Available in Japan: Novartis
February 8, 2022
- Kyoto Univ. Spinoff, CiRA, AZ to Develop Method to Produce iPSC-Derived Renal Tissues
February 8, 2022
- Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
- Meiji Unit Slapped with £4.62 Million Fine over Anti-Competitive Practices in UK
February 8, 2022
- Kyorin Holdings to Merge Pharma Subsidiary in April 2023
February 7, 2022
- Opdivo Tops Japan Sales Ranking in January: Encise
February 7, 2022
- Aculys Pharma Begins Japan PI for Narcolepsy Drug Candidate
February 7, 2022
- Fujifilm to Boot Up Corporate Venture Capital for Life Science
February 7, 2022
- Mochida Files Inhaled Treprostinil for PAH in Japan
February 7, 2022
- Pharma Industry Frets Cost and Deadline of MHLW-Ordered Carcinogen Risk Inspections
February 7, 2022
- Eisai Aims for US Accelerated OK for Lecanemab in 2022; Japan/EU Filing Planned by March 2023
February 4, 2022
- Mitsubishi Tanabe’s 9 Month Sales Rise Fueled by Strong Growth in Stelara
February 4, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…